Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice
| Autor: | Ivar P. E. Gondrie, Nico G. Hartwig, Linda C. van der Knaap, Petronette van Jaarsveld, Diane E. T. Bastiaans, Eline G. Visser, Pieter L. A. Fraaij, Annemarie M. C. van Rossum, David M. Burger, Gertjan J. Driessen, Ronald de Groot |
|---|---|
| Přispěvatelé: | Pediatrics |
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Microbiology (medical) Pediatrics medicine.medical_specialty Adolescent Sustained Virologic Response Anti-HIV Agents 030106 microbiology lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] Lopinavir/ritonavir HIV Infections Kaplan-Meier Estimate Lopinavir 03 medical and health sciences SDG 3 - Good Health and Well-being medicine Humans Dosing Child Adverse effect Ritonavir medicine.diagnostic_test business.industry Infant Viral Load 030112 virology Regimen Infectious Diseases lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Therapeutic drug monitoring Child Preschool Pediatrics Perinatology and Child Health HIV-1 Female business Viral load Follow-Up Studies medicine.drug |
| Zdroj: | Pediatric Infectious Disease Journal, 36, 976-980 Pediatric Infectious Disease Journal, 36, 10, pp. 976-980 Pediatric Infectious Disease Journal, 36(10), 976-980. Lippincott Williams & Wilkins |
| ISSN: | 0891-3668 |
| Popis: | Contains fulltext : 176929.pdf (Publisher’s version ) (Closed access) BACKGROUND: The use of lopinavir/ritonavir once-daily (LPV/r QD) has not been approved for children. Good short-term clinical, virologic and immunologic outcomes have been observed in children on LPV/r QD. METHODS: We evaluated the long-term effectiveness of a LPV/r QD containing regimen in HIV-1-infected children in clinical practice. Selected children (0-18 years of age) with an undetectable HIV-1 RNA viral load (400 copies/mL twice within 6 months). Also, the exposure to LPV on the initial once-daily dosing regimen was determined. RESULTS: Forty children (median age: 6.5 years; range: 1.0-17) were included. Median follow-up was 6.3 years (range: 1.0-10.3). During yearly follow-up, the percentage of children with an undetectable viral load varied between 82% and 100% (on treatment) and 83% and 93% (last observation carried forward). Five children (12.5%) met the criteria for failure. CD4+ and CD8+ counts remained stable at normal values. Geometric mean LPV area under the plasma concentration-time curve (linear up-log down method) over a dosing interval from time 0 to 24 hours after dosing was 169.3 mg x h/L, and last observed drug concentration was 1.35 mg/L. Adverse events were encountered in 8 patients, were mainly gastrointestinal, and in these cases, no reason to stop treatment. CONCLUSION: A once-daily LPV/r-containing regimen in HIV-1-infected children with intensive clinical and therapeutic drug monitoring is well tolerated and has good long-term clinical, virologic and immunologic outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|